A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Fibroblast growth factors (FGFs) signal through FGF receptor ... Recombinant FGF7 is Food and Drug Administration approved for the treatment of chemoradiation-induced oral mucositis.

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug development strategy with plans for multiple new candidates this year.

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...

The company is expected to see accelerated revenue growth ... GLP-1 drug Orforglipron for diabetes and weight loss, and Donanemab for Alzheimer’s disease. Another significant factor contributing ...